Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2021-06-23 Board/Management Inform…
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
210621_Informacja dot Zbigniewa Molenda
Board/Management Information Classification · 95% confidence The document text is in Polish and details specific information about an individual, Zbigniew Molenda, who is a member of the Supervisory Board ('Członek Rady Nadzorczej'). It lists his appointment date, function, education, previous positions, and other roles held in related or associated companies. This structure strongly aligns with regulatory requirements for disclosing information about company directors or supervisors, often related to corporate governance or insider status. Given the options, this content is most closely related to Board/Management Information (MANG), as it concerns the composition and background of the supervisory body, rather than a general governance report (CGR) or director's personal trading (DIRS). The reference to the Minister of Finance regulation further confirms its nature as a mandatory disclosure regarding management personnel.
2021-06-23 Polish
210621_Informacja dot. Anny Janickej
Board/Management Information Classification · 98% confidence The document provides detailed biographical and professional information about Anna Janicka, a member of the Supervisory Board ('Rada Nadzorcza'). The header explicitly mentions 'Informacje dotyczące Pani Anny Janickiej - członka Rady Nadzorczej' and references Polish financial regulations concerning information disclosure about board members. This content directly relates to the composition and background of the company's management/supervisory body, fitting the definition of Board/Management Information.
2021-06-23 Polish
210621_Informacja dot Jerzego Gebickiego
Board/Management Information Classification · 98% confidence The document text is in Polish and details specific information about a member of the Supervisory Board ('Członek Rady Nadzorczej'), Professor Jerzy Gębicki. It lists his appointment date, qualifications, professional history, and other business activities, referencing a specific regulation from the Polish Minister of Finance regarding current and periodic information disclosed by issuers of securities. This structure strongly suggests a mandatory disclosure related to the composition or changes within the company's governing body (Board of Directors/Supervisory Board). This aligns directly with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2021-06-23 Polish
210621_Informacja dot Agnieszki Dziki
Board/Management Information Classification · 99% confidence The document text is a formal disclosure in Polish regarding a member of the Supervisory Board ('Członek Rady Nadzorczej'), Agnieszka Dziki. It details her appointment date, function, professional background, and other business activities, referencing specific Polish financial regulations ('Rozporządzenia Ministra Finansów'). This content directly relates to the composition and background of the company's management or supervisory body. This aligns perfectly with the definition of Board/Management Information (MANG). The document is not a general earnings release, annual report, or a transaction report, but a specific disclosure about a director.
2021-06-23 Polish
210621_Informacja dot Jacka Dauenhauera
Board/Management Information Classification · 98% confidence The document text is in Polish and details information about an appointed member of the Supervisory Board ('Członek Rady Nadzorczej'), Jacek Dauenhauer. It lists his appointment date, function, education, previous positions, and other roles held outside the issuer. This structure, focusing on the background and roles of a director/manager, directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is a specific disclosure regarding a board member's profile, not a general financial report or a proxy statement.
2021-06-23 Polish
Powołanie członków Rady Nadzorczej na nową kadencję - Content (PL)
Board/Management Information Classification · 98% confidence The document text explicitly states that the Management Board (Zarząd) of PHARMENA S.A. informs about the Ordinary General Meeting (Zwyczajne Walne Zgromadzenie) held on June 22, 2021. The key action taken was the adoption of resolution no. 16 concerning the appointment of the Supervisory Board (Rada Nadzorcza) for a new term due to the expiration of the previous term. This content directly relates to changes in the company's board structure and appointments following a shareholder meeting. This aligns perfectly with the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors. Although an AGM occurred, the focus is on the resulting board appointments, not the AGM materials themselves (AGM-R) or the voting results (DVA).
2021-06-23 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.